Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Inclusion Criteria: Treatment Portion: * AML in 1st remission - for patients whose AML does not have "good risk" cytogenetic features (i.e. t (8;21), t(15;17), inv 16 without c-kit mutations). * Acute leukemias of ambiguous lineage in ≥ 1st remission * Secondary AML in remission * AML in ≥ 2nd remission * ALL in 1st remission with clinical or molecular features indicating a high risk for relapse; or ALL ≥ 2nd remission * CML failing to respond to or not tolerating imatinib, dasatinib or nilotinib in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in CR after accelerated phase or blast crisis. * Non-Hodgkins lymphoma with chemo responsive disease in any of the following categories: intermediate or high grade lymphomas who have failed to achieve a first CR or have relapsed following a 1st remission who are not candidates for autologous transplants. b.ii. any NHL in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant. * Myelodysplastic syndrome (MDS): RA/RCMD with high risk cytogenetic features or transfusion dependence, RAEB-1 and RAEB-2 * Chronic myelomonocytic leukemia: CMML-1 and CMML-2. * Patient's age is ≥18 or ≤60 years old * Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status ≥ 70% * Patients must have adequate organ function measured by: Cardiac: asymptomatic or if symptomatic then LVEF at rest must be \> 50% and must improve with exe…